阿里健康(00241.HK)成立天貓好藥聯盟 年內建12個藥品倉庫
阿里健康(00241.HK)宣布聯合全球百強知名藥企成立天貓好藥聯盟,平台將從生產源頭打關,符合標準的藥品都將配有「天貓好藥」字樣標識,以供消費者識別。產品頁面將附有用藥知識、使用禁忌、使用說明以及藥師在線服務,指導消費者安全合理用藥。
阿里健康首席運營官、醫藥電商負責人沈滌凡表示,全國逾百個城市的用戶,購買天貓好藥產品均可享受專業藥品物流的次日達服務。未來一年內將建設12個藥品倉庫,推進全國物流提速,讓更多三線以下城市以及偏遠地區有好藥可用。
該平台亦將為藥企品牌提供從新品上市、全媒體投放、會員運營、零售激活在內的全套數字化解決方案,協助醫藥產業數字化升級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.